Status:
COMPLETED
Safety & Efficacy of Thalidomide in Children With Transfusion Dependent Thalassemia
Lead Sponsor:
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Conditions:
Transfusion-dependent Thalassemia
Eligibility:
All Genders
3-18 years
Phase:
PHASE1
Brief Summary
Transfusion Dependent Thalassemia (TDT) is emerging as a global public health concern. Hemopoietic stem cell transplantation (HSCT) is the only curative treatment. But its adoption is limited due to l...
Detailed Description
Study design: Quasi-randomized controlled tria Period of Study: From March 2023 to February 2023 Place of study: Department of Pediatric Hematology \& Oncology, Bangabandhu Sheikh Mujib Medical Uni...
Eligibility Criteria
Inclusion
- Patients diagnosed as transfusion dependent thalassemia
- Age ranged from 3-18 years
- Blood transfusion for more than 1 year.
Exclusion
- Active systemic illness,
- Abnormal liver and kidney functions;
- Severe cardiopulmonary or cerebrovascular diseases;
- Recent fracture or recent major surgery
- Use of drugs that might affect Hb levels 3 months before enrollment;
- Any bleeding disorder .
Key Trial Info
Start Date :
March 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 28 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06098014
Start Date
March 1 2023
End Date
February 28 2024
Last Update
April 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bangabandhu Sheikh Mujib Medical University
Dhaka, Bangladesh, 1000